These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27779692)

  • 1. Angiomotin promotes the malignant potential of colon cancer cells by activating the YAP-ERK/PI3K-AKT signaling pathway.
    Zhang Y; Yuan J; Zhang X; Yan F; Huang M; Wang T; Zheng X; Zhang M
    Oncol Rep; 2016 Dec; 36(6):3619-3626. PubMed ID: 27779692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.
    Hsu YL; Hung JY; Chou SH; Huang MS; Tsai MJ; Lin YS; Chiang SY; Ho YW; Wu CY; Kuo PL
    Oncogene; 2015 Jul; 34(31):4056-68. PubMed ID: 25381822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiomotin promotes breast cancer cell proliferation and invasion.
    Lv M; Lv M; Chen L; Qin T; Zhang X; Liu P; Yang J
    Oncol Rep; 2015 Apr; 33(4):1938-46. PubMed ID: 25647626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiomotin Family Members: Oncogenes or Tumor Suppressors?
    Lv M; Shen Y; Yang J; Li S; Wang B; Chen Z; Li P; Liu P; Yang J
    Int J Biol Sci; 2017; 13(6):772-781. PubMed ID: 28656002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
    Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
    Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP.
    Lv M; Li S; Luo C; Zhang X; Shen Y; Sui YX; Wang F; Wang X; Yang J; Liu P; Yang J
    Oncotarget; 2016 Mar; 7(11):12393-403. PubMed ID: 26848622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.
    Yi C; Shen Z; Stemmer-Rachamimov A; Dawany N; Troutman S; Showe LC; Liu Q; Shimono A; Sudol M; Holmgren L; Stanger BZ; Kissil JL
    Sci Signal; 2013 Sep; 6(291):ra77. PubMed ID: 24003254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of localization and function of the transcriptional co-activator YAP by angiomotin.
    Moleirinho S; Hoxha S; Mandati V; Curtale G; Troutman S; Ehmer U; Kissil JL
    Elife; 2017 May; 6():. PubMed ID: 28464980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
    Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
    J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced expression of AMOT reverses adriamycin resistance in breast cancer cells.
    Zhang H; Wang Y; Gao Y; Du M; Pan E; Sun M; Zhang X
    Cell Biol Int; 2024 Sep; 48(9):1301-1312. PubMed ID: 39021301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMOT is required for YAP function in high glucose induced liver malignancy.
    Liu Y; Lu Z; Shi Y; Sun F
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1555-1561. PubMed ID: 29217192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiomotin'g YAP into the nucleus for cell proliferation and cancer development.
    Hong W
    Sci Signal; 2013 Sep; 6(291):pe27. PubMed ID: 24003252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of tricellular tight junction protein LSR promotes cell invasion and migration via upregulation of TEAD1/AREG in human endometrial cancer.
    Shimada H; Abe S; Kohno T; Satohisa S; Konno T; Takahashi S; Hatakeyama T; Arimoto C; Kakuki T; Kaneko Y; Takano KI; Saito T; Kojima T
    Sci Rep; 2017 Jan; 7():37049. PubMed ID: 28071680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer.
    Ling HH; Kuo CC; Lin BX; Huang YH; Lin CW
    Exp Cell Res; 2017 Jan; 350(1):218-225. PubMed ID: 27914787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.
    Wang W; Li N; Li X; Tran MK; Han X; Chen J
    Cell Rep; 2015 Oct; 13(3):524-532. PubMed ID: 26456820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.
    Wang J; Wang H; Zhang Y; Zhen N; Zhang L; Qiao Y; Weng W; Liu X; Ma L; Xiao W; Yu W; Chu Q; Pan Q; Sun F
    Cell Signal; 2014 May; 26(5):1048-59. PubMed ID: 24468535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner.
    Liu Y; Wang G; Yang Y; Mei Z; Liang Z; Cui A; Wu T; Liu CY; Cui L
    Oncogene; 2016 May; 35(21):2789-800. PubMed ID: 26387538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VASN promotes colorectal cancer progression by activating the YAP/TAZ and AKT signaling pathways via YAP.
    Liang W; Zuo J; Liu M; Su Y; Guo B; Hou J; Xing Q; Peng Y; Fang L; Cao Y; Shan J; Sun R; Zhao J; Wang J
    FASEB J; 2023 Jan; 37(1):e22688. PubMed ID: 36468780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S; McCollum D
    J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways.
    Chen B; Zeng X; He Y; Wang X; Liang Z; Liu J; Zhang P; Zhu H; Xu N; Liang S
    Oncotarget; 2016 Nov; 7(44):71400-71416. PubMed ID: 27662663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.